when to initiate antiretroviral therapy in hiv-infected patients
DESCRIPTION
Guía InicioTRANSCRIPT
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 1/13
OfficialreprintfromUpToDate www.uptodate.com2015UpToDate
AuthorJohnGBartlett,MD
SectionEditorMartinSHirsch,MD
DeputyEditorJenniferMitty,MD,MPH
WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
Alltopicsareupdatedasnewevidencebecomesavailableandourpeerreviewprocessiscomplete.Literaturereviewcurrentthrough:Dec2014.|Thistopiclastupdated:Oct23,2014.
INTRODUCTIONAtthetimeoftheintroductionofpotentcombinationantiretroviraltherapy(ART)in1996,therewasa"hithardandhitearly"approachtotreatment[1].However,whenthetoxicitiesandresistanceofchronicARTbecameapparentandcomplicateddosingregimensthwartedadherence,thependulumswungbacktowithholdingtherapyinpatientswithrelativelypreservedCD4Tcellcounts.
AdvancesinHIVtherapyinthelastdecadehaveshiftedtheriskbenefitratiotoearliertreatment.HIVtreatmentguidelinesfromtheUnitedStatesDepartmentofHealthandHumanServices(DHHS)andtheInternationalAntiviralSocietyUSAPanelnowrecommendantiretroviraltreatmentinallpatientswithHIVinfection,regardlessofCD4cellcounts[2,3].Thistopicwilldiscussthestrengthoftheevidencesupportingthesetreatmentguidelines.
Theselectionofspecificmedications,patientevaluation,counselingregardingsideeffects,andlaboratorymonitoringarediscussedelsewhere.(See"CounselingHIVinfectedpatientsregardingpotentialsideeffectsofantiretroviraltherapy"and"PatientmonitoringduringHIVantiretroviraltherapy"and"SelectingantiretroviralregimensforthetreatmentnaveHIVinfectedpatient"and"Considerationspriortoinitiatingantiretroviraltherapy".)
GOALSOFTHERAPYTheprimarygoalsofcombinationantiretroviraltherapyaretoincreasediseasefreesurvivalthroughsuppressionofHIVreplicationandimprovementinimmunologicfunction[2,3].ViralsuppressionalsodecreasestheriskofHIVtransmissiontoanuninfectedsexualpartner[46].
INDICATORSOFIMMUNEFUNCTIONTheCD4cellcountisthemainindicatorofimmunefunctioninpatientswhoareHIVinfectedandisthestrongestpredictorofdiseaseprogressionandsurvival[2,7,8].Itisalsooneofthekeyfactorsindecidingwhethertoinitiatechemoprophylaxisforopportunisticinfectionsandtoevaluateclinicalcomplications.(See"OverviewofprimarypreventionofopportunisticinfectionsinHIVinfectedpatients".)
RATIONALEFORTREATMENTOFALLHIVINFECTEDPATIENTSThebenefitsofantiretroviraltherapy(ART)indecreasingmorbidityandmortalityinpatientswithCD4cellcounts200cells/microLwereheavilyinfluencedbyreportedtoxicities,drugresistance,andlimitedtreatmentoptions[3].ThesupportiveargumentsfortreatmentofallHIVinfectedpatientsaremany,andinclude[917]:
Therapeuticoptionshaveexpanded
Thedrugsaremorepotentthanearlieragents
Drugtoxicityhasdeclinedanddrugtolerabilityhasimproved
Simplifiedregimenshaveledtoimprovedadherence
UntreatedHIVinfectionhasnegativeconsequencesonothercomorbidities,suchascoronaryarterydisease,liverandkidneydisease,neurologicdisease,andmalignancy,whichmaybepartlymediatedbyinflammationandproinflammatorycytokines
Earliertherapyappearstoleadtoamorerobustimmunologicrecoverycomparedwithdeferredtherapy
SuppressiveARTprovidesanimportantpotentialpublichealthbenefitbydecreasingtheriskofsexual
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 2/13
Argumentsfordelayedtherapyincludethefollowing:
CONSEQUENCESOFDEFERREDTREATMENTDelayedtreatmentcanleadtosubtherapeuticresponsestotreatmentandimmunologicdecline.
RiskofvirologicfailureOneobservationalcohortstudyin7916HIVinfectedpatientswhoinitiatedantiretroviraltherapy(ART)demonstratedthattheriskofvirologicfailuretothreedrugclassesovera10yearperiodwasincreasedinthosepatientswhohadabaselineCD4cellcount200cells/microL(12versus6percent)[18].
IncompleteimmunologicrecoverySomeresearchershaveadvocatedearliertherapeuticinterventionbecauseofconcernsthatimmunologicrecoverymaynotbecompleteiftreatmentisinitiatedlateininfection[1923].
TheseobservationaldatasuggestthatimmunologicrecoveryismorerobustifARTisinitiatedathigherCD4cellcounts.
ProgressionofimmunologicdeclineOnelargecohortstudyof3631patientswhohadabaselineCD4cellcount>500cells/microLfoundthatthemediantimetoprogresstoaCD4countof
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 3/13
HIVassociatednephropathyHIVassociatednephropathyisthemostcommoncauseofkidneydiseaseinHIVinfectedpatientsandcanoccuratanyCD4cellcount[31,32].SincetheintroductionofpotentART,theincidenceofHIVrelatedendstagerenaldiseasehasdeclined,andthisdiseaseisnowuncommonamongpatientswithviralsuppressiononART[33,34].AnecdotalobservationsofimprovedrenalfunctionwithHIVRNAsuppressiononARTamongthosewithbaselinerenalinsufficiencyalsosupporttheseobservations[2,3538].(See"HIVassociatednephropathy(HIVAN)".)
HIVassociatedneurocognitivedeficitsTheincidenceofHIVassociateddementiahasdeclinedsincetheintroductionofpotentART.Inonecohort,patientswithviralsuppressiononARThadalowerriskofHIVassociateddementiathanpatientswithdetectableplasmaHIVRNA[39].ObservationaldataalsosuggestthatpatientswithHIVdementiaimproveclinicallyaftertheinitiationofHIVtherapy.(See"HIVassociatedneurocognitivedisorders".)
MalignancyLargecohortstudieshavereportedalinkbetweenCD4count350to500cells/microLanduncontrolledHIVviremiaandtheriskofAIDSand/ornonAIDSdefiningmalignancies[4043].ThepotentialeffectofHIVassociatedimmunodeficiencyisparticularlystrikingforcancersassociatedwithotherviralinfections,suchashepatitisB,hepatitisC,humanpapillomavirus,andEpsteinBarrvirus[40,44].(See"HIVinfectionandmalignancy:Epidemiologyandpathogenesis".)
Inaddition,severalpopulationbasedanalysessuggestthattheincidenceofAIDSandnonAIDSassociatedmalignancieshasdeclinedwiththeeraofpotentART[45,46].
CardiovasculardiseaseMarkersofinflammation(eg,interleukin6)andcoagulation(eg,Ddimer)appeartostronglycorrelatewithHIVreplicationandanincreasedriskofcoronaryarterydisease[10].IntheSMARTstudy,theriskofcardiovasculareventswasgreaterinthoserandomlyassignedtotreatmentinterruptionratherthancontinuoustherapy[29].Observationaldataalsosuggestthatimmunosuppressionmaybeassociatedwithanincreasedriskofcardiovasculardisease[47].(See"EpidemiologyofcardiovasculardiseaseandriskfactorsinHIVinfectedpatients".)
Sincesomeantiretroviralagentsarealsoassociatedwithinsulinresistanceandcardiovascularevents,carefulselectionofinitialagentsisneeded.(See"EpidemiologyofcardiovasculardiseaseandriskfactorsinHIVinfectedpatients"and"Epidemiology,clinicalmanifestations,anddiagnosisofHIVassociatedlipodystrophy".)
HepatitisBinfectionVarioustreatmentguidelinessuggestusingantiviralagentswithdualactivityagainstbothHIVandhepatitisBvirus(HBV)intheHIVinfectedpatientwhorequiresHBVtherapy,regardlessofCD4cellcount[2,3].ThetreatmentofhepatitisBintheHIVinfectedpatientisdiscussedelsewhere.(See"Epidemiology,clinicalmanifestations,anddiagnosisofhepatitisBintheHIVinfectedpatient"and"TreatmentofchronichepatitisBintheHIVinfectedpatient".)
HepatitisCinfectionHepaticfibrosisprogressionratesmaybeslowerinduallyinfectedpatientstakingART.ThetreatmentofhepatitisCvirusintheHIVinfectedpatientisdiscussedindetailelsewhere.(See"TreatmentofhepatitisCvirusinfectionintheHIVinfectedpatient".)
AgingHIVinfectionisassociatedwithimmunosenescence.StudiesduringtheearlyAIDSepidemicdemonstratedthatpatientsovertheageof50haveamorerapidprogressiontoAIDSandpooreroverallsurvivalfollowingHIVseroconversioncomparedwithyoungerpatients[48].IntheeraofpotentART,studieshavealsosuggestedthatolderpatientsmayhavedelayedimmunerecovery.
Whentherapyisinitiated,patientsshouldbecarefullycounseledaboutpotentialsideeffects,sincepharmacokineticdatainthispatientpopulationarescant.(See"HIVandtheolderpatient".)
IMPACTOFARTONHIVTRANSMISSION
DiscordantcouplesAnotherrationaleforearlyantiretroviraltherapy(ART)initiationistopreventHIVtransmissionfromanHIVseropositivepersontoanHIVseronegativesexualpartner[49].
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 4/13
Ametaanalysiswasperformedin5021heterosexualdiscordantcoupleswith461HIVtransmissioneventstodeterminetheroleofARTinpreventionoftransmission.TherewerenotransmissioneventstoaseronegativepartneramongthoseHIVseropositiveindividualswhohadachievedviralsuppressiononART[4].Asubsequentclinicaltrialamong1763HIVserodiscordantcouples(HIVPreventionTrialsNetworkHPTN052)demonstratedthatimmediateARTinitiationwasassociatedwitha96percentreductioninHIVtransmissioncomparedwithdelayedtherapy[5,6].Adetaileddiscussionontreatmentaspreventionisfoundelsewhere.(See"HIVtreatmentasprevention".)
PregnancyARTisrecommendedinpregnantwomenbyvariousguidelinepanels,regardlessofCD4cellcount,todecreaseratesofperinatalHIVtransmissionaswellastotreatthemother[50].Theevidenceforthisrecommendation,thetimingofARTrelativetostageofpregnancy,andthechoiceofagentsthataresafeinpregnancy,arefoundelsewhere.(See"PrenatalevaluationandintrapartummanagementoftheHIVinfectedpatientinresourcerichsettings"and"UseofantiretroviralmedicationsinpregnantHIVinfectedpatientsandtheirinfantsinresourcerichsettings".)
InjectiondrugusersModelssuggestthatacombinationofARTforHIVinfectedpersonswhoinjectdrugs,combinedwithopioidsubstitutionprogramsandneedleexchangeprograms,havethepotentialtoreduceHIVtransmissiontoHIVuninfectedinjectiondrugusersby50percent[51].
IMPACTOFARTONRISKOFMORTALITYFROMOPPORTUNISTICINFECTIONSAntiretroviraltherapy(ART)isalsoeffectiveinreducingmortalityamongpatientswithadvancedimmunosuppressionwhopresentwithacuteopportunisticinfections(OIs):
THECLINICALBENEFITOFARTVARIESBYBASELINECD4CELLCOUNT
GeneralbackgroundEpidemiologicdatahavedemonstratedthattheintroductionofpotentthreedrugcombinationregimensofantiretroviraltherapy(ART)in1996ledtoremarkabledeclinesinmorbidityandmortalityamongHIVinfectedpatients[5456].ThestrengthoftheevidenceforimprovedsurvivalincreasesastheCD4countdeclines.
TheimpactofthepatientsbaselineCD4cellcountontreatmentoutcomeswaswellillustratedinacollaborativestudy(HIVCAUSALCollaboration)of62,760treatmentnaivepatientsinEuropeandtheUnitedStates[57].Overameanfollowupof3.3years,2039patientsdied.Theoverallriskofmortalitywasreducedbyapproximately50percentamongthosewhoinitiatedARTcomparedwiththosewhodidnot.However,theabsolutesurvivalbenefitdependedonthepatientslevelofimmunocompromisebeforetreatment.InanalysesstratifiedbyCD4cellcount,thecorrespondinghazardratiosformortalityfortreatedversusuntreatedpatientswere:
RepresentativestudiesthatsupporttheinitiationofARTwithinvariousCD4cellcountstrataarediscussedbelow.
PatientswithCD4counts200cells/microLClinicaltrials,cohortanalysesandmetaanalyseshavedefinitivelyshownthatpotentARTimprovessurvivalandreducesAIDSrelatedcomplicationsinpatientswithadvanceddisease[50,5860]:
Inarandomizedtrialof282patientspresentingwithvariousOIs,"earlyART"(initiatedwithin14daysofpresentation)ledtoa50percentreductioninAIDSrelatedmortalitycomparedwith"lateART"(initiatedwhenOItreatmentwascompleted)withoutanyincreaseintreatmentrelatedadverseevents[52].AsurvivalbenefitofearlyARThasbeenshownbyothergroupsaswell[53].
0.29forpatientswith500cells/microL(95%CI0.581.01)
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 5/13
PatientswithCD4counts200350cells/microLMultiplelargeobservationalstudiesandarandomizedcontrolledtrialsuggestthatpatientswithCD4cellcountsbetween200and350cells/microLalsobenefitfromART[24,6165]:
PatientswithCD4counts350to500cells/microLObservationaldataandonecontrolledtrialsuggestthatinitiationofARTinpatientswithCD4countsbetween350and500cells/microLdecreasesAIDSrelatedeventsandimprovessurvival[14,57,66,67].
TheclinicalbenefitofARTwasdemonstratedintheHIVPreventionNetworkTrial052,whichenrolled1763HIVserodiscordantcouplestoassesstheefficacyofARTinpreventingHIVtransmission[5].Thepreventionaspectsofthetrialarediscussedabove.(See'ImpactofARTonHIVtransmission'above.)
Inthistrial,HIVinfectedtreatmentnavepartnerswereeligibleforARTiftheirCD4countwasbetween350and550cells/microL.Serodiscordantcoupleswererandomlyassignedtothe"earlyART"arm(initiationofHIVtreatmentatenrollment)orthe"delayedART"arm(initiationofHIVtreatmentwhentheCD4countdroppedbelow250cells/microLorafteranAIDSrelatedillness).PatientsintheearlytherapyarmhadalowerriskofanHIVrelatedclinicaleventthanthoseinthedelayedtherapyarmoverthe1.7yearperiodoffollowup(HR0.5995%CI0.400.88).Thedifferenceintherateofclinicaleventswasmostcloselyassociatedwiththeincidenceofextrapulmonarytuberculosis,whichoccurredmainlyamongpatientsfromendemicareas(3versus17casesintheearlyanddelayedgroups,respectively).Nodifferencesinmortalityrateswereseenbetweenthearms.(See"HIVtreatmentasprevention".)
OneoftheobservationalstudiesthatsupportsinitiationofARTamongpatientswithinthe350to500CD4cellcountstratum(NAACCORD)isdiscussedbelow.
PatientswithCD4counts>500cells/microLTherearefewerobservationaldataontheuseofARTinpatientswithCD4cellcounts>500cells/microLcomparedwithpatientswithlowerCD4cellcountsandtherearenorandomizedcontrolledtrialsthathaveexaminedtheefficacyofthisapproach[67].
NAACCORDstudyTwoparallelanalysesinvolvingatotalof17,517asymptomaticHIVinfectedpatientswhohadnotreceivedpriorARTwereanalyzedbasedonoutcomedatafromcohortstudiesconductedfrom1996
Arandomizedtrial(ACTG320)in1156patientswithCD4cellcounts350/microLwererandomlyassignedtoaCD4cellcountguidedstrategyofresumingtherapyonlywhentheCD4countwas
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 6/13
through2005intheUnitedStatesandCanada(ie,theNAACCORDstudy)[67].PatientswerestratifiedintotwogroupsaccordingtotheirCD4cellcountatbaseline(351to500cellsor>500cells/microL).Ineachgroup,comparisonsweremadeintherelativeriskofdeathforpatientswhoinitiatedtherapywhentheCD4cellcountwasaboveeachofthetwothresholds(earlytherapygroup)withthatofpatientswhostartedtherapyaftertheirCD4cellcountshadfallenbelowthesethresholds(deferredtherapygroup).
Afteradjustmentsforpotentialconfounders,thetwoanalysesdemonstratedthatdeferredtherapywasassociatedwithincreasedmortalityatbothCD4cellcountthresholds,comparedwithearlytreatment:
Limitationsofthisobservationalstudyincludethesmallnumberofdeathsobserved,thelackofdataconcerningcauseofdeathandthepossibilitythatpatientswhostartedARTathighCD4cellcountsmayalsohaveother"healthseekingbehaviors"thatcontributedtotheoutcomesobserved[68].Furthermore,asubstantialproportionofpatientswhodeferredARTandyetmaintainedstableCD4cellcountswerenotincludedintheanalysis.Itis,thus,unclearifthissubsetofpatientswouldhavealsobenefitedfromearlytreatment[68].Finally,thereisnoinformationondrugtoxicity,andtheexactcauseofdeathwasonlyknownfor16percentofthepatientpopulation.
TheSTARTtrialArandomizedcontrolledtrialisinprogresstoaddressthetimingofARTwithrespecttospecificCD4strata.Someexpertsareconcernedthatbythecompletionofthistrialin2015orlater,theresultswillnolongerberelevanttocontemporaryclinicalpractice[69].
TREATMENTRECOMMENDATIONSWeagreewiththe2014HIVtreatmentguidelinesfromtheUnitedStatesDepartmentofHealthandHumanServices(DHHS)andthe2014InternationalAntiviralSocietyUSAPanelthatrecommendantiretroviraltherapy(ART)beofferedtoallHIVinfectedpatients,includingasymptomaticpatients,regardlessofimmunestatus[2,3].ThestrengthoftheevidencesupportingthisrecommendationvariesbythepretreatmentCD4cellcount,asdiscussedbelow.
PatientswithaCD4count500cells/microLInpatientswithCD4countsgreaterthan500cells/microL,wesuggestinitiationofARTbasedonthefollowingrationale:
Among8362patients,2084(25percent)initiatedARTwithaCD4cellcountof351to500/microL,whiletherestdeferredtherapy.Therewasasignificantincreaseintheriskofdeathinthedeferredversusearlytherapygroup(relativerisk1.69,95%CI1.262.26).Thisanalysiswasbasedonatotalof375deathsinbothgroupscombined.
Among9155patients,2220(24percent)initiatedARTataCD4cellcountofmorethan500cells/microL,whiletherestdeferredtherapy.Therewasasignificantincreaseintheriskofdeathinthedeferredversusearlytherapygroup(relativerisk1.94,95%CI1.372.79).Thisanalysiswasbasedonatotalof311deathsinbothgroupscombined.
InitiationofARTinpatientswithahistoryofanAIDSdefiningillnessoraCD4count
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 7/13
SomeobservationaldatasuggestasurvivalbenefitwithearlierinitiationoftreatmentatCD4cellcounts>500cells/microLcomparedwithdelayedtreatment[67].However,thepotentialbenefitofARTneedstobebalancedagainstthepossibletoxicitiesassociatedwithlongtermtreatment.Longtermclinicaloutcomesinsuchpatientsarenotavailable.
AnongoinginternationalclinicaltrialisexaminingtheoptimaltimeforasymptomaticHIVinfectedpatientswithCD4cellcounts>500cells/microLtobeginART,althoughtheresultswillnotbeavailableforseveralyears.Thus,patientpreferenceand/or"readiness"shouldplayanimportantroleinthedecisiontoinitiatetherapy,pendingresultsofthedefinitivetrial.Patientsshouldbeadvisedofallthepotentialbenefitsnotedabove,butthattheriskofanAIDSornonAIDSrelatedeventsecondarytountreatedHIVinfectionisgenerallylowamongpatientswithCD4cellcount>500cells/microLcarefulconsiderationissuggestedbeforeafinaldecisionismade[13,67].
OtherpatientsubgroupsWithoutHIVtreatment,asmallsubsetofpatients(2to3percent)areabletomaintainnormalCD4cellcountsformanyyears("longtermnonprogressors")whileanevensmallersubset(0.5to1percent)areabletomaintainviralsuppressionwithviralloads
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 8/13
Eachpatientmustbeevaluatedfortheir"readiness"tostartdailyantiretroviraltherapy.Theprovidermustdevotetimetoeducatethepatientregardingthenegativeimpactofpooradherenceontheriskofdrugresistance.
AdelayofARTismuchmoreconsequentialamongpatientswithlowCD4cellcounts,AIDSdefiningconditions,acuteopportunisticinfections,abaselineviralload>100,000c/mLorarapidlydecreasingCD4count(>100cells/microLperyear).Treatmentdelaymayalsohavesignificantconsequencesinpatientswithothercomorbidities,suchasHIVassociatednephropathyorviralhepatitis.Whenconcernspersistabouttreatmentreadinessinapatientwithadvancedimmunosuppression(
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sourc 9/13
Treatmentrecommendations
AntiretroviraltherapydecreasestheriskofHIVtransmission
'Consequencesofdeferredtreatment'above.)
UntreatedHIVinfectionisalsoariskfactorfordevelopingcoronaryarterydisease,kidneydisease,liverdisease,neurocognitivedeficits,andnonHIVassociatedmalignancy.SomeoftheseobservationsmayberelatedtoHIVinducedproinflammatorycytokines,chronicinflammation,andTcellactivation,leadingtoendorgandamage.Inarandomizedcontrolledstudyofstructuredtreatmentinterruptions,higherratesofmortalityrelatedtocancer,myocardialinfarction,andliverrelateddeathsoccurredinpatientswhostoppedARTcomparedwiththosewhocontinuedART.(See'ImpactofARTonriskofothercomorbidities'above.)
AmajorpublichealthrelatedrationaleforearlyARTinitiationistopreventHIVtransmissionfromanHIVseropositivepersontoanHIVseronegativesexpartnerandfromanHIVinfectedpregnantwomantoanuninfectedinfant.ThesepreventivehealthbenefitsmayalsoapplytoHIVdiscordantinjectiondruguserswhosharedrugparaphernalia.(See'ImpactofARTonHIVtransmission'above.)
Sincetheintroductionofpotentthreedrugcombinationantiretroviralregimens,epidemiologicdatahavedemonstratedremarkabledeclinesinmorbidityandmortalityamongHIVinfectedpatients.ThestrengthoftheevidenceforimprovedclinicaloutcomesincreasesastheCD4countdeclines.(See'TheclinicalbenefitofARTvariesbybaselineCD4cellcount'above.)
GuidelinesfromtheUnitedStatesDepartmentofHealthandHumanServicesandtheInternationalAntiviralSocietyUSAPanelrecommendtreatmentofallpatientswithHIVinfectionregardlessofCD4Tcellcounts.
ForpatientswithaCD4count500/microL,whoaremotivatedtobetreated,wesuggestinitiationofantiretroviraltherapy(Grade2C).PatientsshouldbeadvisedthatthereislessevidenceforthepotentialbenefitsoftreatmentatearlierstagesofHIVinfection,andthedecisiontotreatneedstobebalancedagainstpotentialtoxicitiesoflongtermtherapy.Aclinicaltrial,whichisevaluatingthesafetyandefficacyofARTamongtreatmentnaivepatientswithCD4cellcounts>500cells/microL,isinprogress.(See'PatientswithCD4counts>500cells/microL'aboveand'PatientswithCD4counts>500cells/microL'above.)
CliniciansshouldexplaintodiscordantheterosexualcouplesthatviralsuppressiononARTdecreasestheriskofHIVsexualtransmissiontotheHIVseronegativepartnersubstantially,butdoesnotcompletelyeliminatetherisk,ortheneedfortraditionalpreventivemeasures(eg,condoms).ItisnotknownifviralsuppressiononARTwouldhaveasimilarbeneficialeffectontransmissionratesamongmenwhohavesexwithmen(MSM)andtheirHIVseronegativepartners.HIVtreatmentforpreventionoftransmissionisdiscussedindetailelsewhere.(See"HIVtreatmentasprevention"and'ImpactofARTonriskofothercomorbidities'above.)
ARTisrecommendedinpregnantwomenbyvariousguidelinecommittees,regardlessofCD4cellcount,to
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sour 10/13
UseofUpToDateissubjecttotheSubscriptionandLicenseAgreement.
REFERENCES
1. HoDD.TimetohitHIV,earlyandhard.NEnglJMed1995333:450.2. PanelonAntiretroviralGuidelinesforAdultsandAdolescents.Guidelinesfortheuseofantiretroviralagents
inHIV1infectedadultsandadolescents.DepartmentofHealthandHumanServices.Availableathttp://catalogo.fucsalud.edu.co:2239/contentfiles/lvguidelines/AdultandAdolescentGL.pdf(AccessedonMay01,2014).
3. GnthardHF,AbergJA,EronJJ,etal.AntiretroviraltreatmentofadultHIVinfection:2014recommendationsoftheInternationalAntiviralSocietyUSAPanel.JAMA2014312:410.
4. AttiaS,EggerM,MllerM,etal.SexualtransmissionofHIVaccordingtoviralloadandantiretroviraltherapy:systematicreviewandmetaanalysis.AIDS200923:1397.
5. CohenMS,ChenYQ,McCauleyM,etal.PreventionofHIV1infectionwithearlyantiretroviraltherapy.NEnglJMed2011365:493.
6. DonnellD,BaetenJM,KiarieJ,etal.HeterosexualHIV1transmissionafterinitiationofantiretroviraltherapy:aprospectivecohortanalysis.Lancet2010375:2092.
7. MellorsJW,MuozA,GiorgiJV,etal.PlasmaviralloadandCD4+lymphocytesasprognosticmarkersofHIV1infection.AnnInternMed1997126:946.
8. EggerM,MayM,ChneG,etal.PrognosisofHIV1infectedpatientsstartinghighlyactiveantiretroviraltherapy:acollaborativeanalysisofprospectivestudies.Lancet2002360:119.
9. LichtensteinKA,ArmonC,BuchaczK,etal.InitiationofantiretroviraltherapyatCD4cellcounts>/=350cells/mm3doesnotincreaseincidenceorriskofperipheralneuropathy,anemia,orrenalinsufficiency.JAcquirImmuneDeficSyndr200847:27.
10. KullerLH,TracyR,BellosoW,etal.InflammatoryandcoagulationbiomarkersandmortalityinpatientswithHIVinfection.PLoSMed20085:e203.
11. TienPC,ChoiAI,ZolopaAR,etal.InflammationandmortalityinHIVinfectedadults:analysisoftheFRAMstudycohort.JAcquirImmuneDeficSyndr201055:316.
12. HarrisonKM,SongR,ZhangX.LifeexpectancyafterHIVdiagnosisbasedonnationalHIVsurveillancedatafrom25states,UnitedStates.JAcquirImmuneDeficSyndr201053:124.
13. StudyGrouponDeathRatesatHighCD4CountinAntiretroviralNaivePatients,LodwickRK,SabinCA,etal.DeathratesinHIVpositiveantiretroviralnaivepatientswithCD4countgreaterthan350cellspermicroLinEuropeandNorthAmerica:apooledcohortobservationalstudy.Lancet2010376:340.
14. PhillipsAN,GazzardB,GilsonR,etal.RateofAIDSdiseasesordeathinHIVinfectedantiretroviraltherapynaiveindividualswithhighCD4cellcount.AIDS200721:1717.
15. NeuhausJ,AngusB,KowalskaJD,etal.RiskofallcausemortalityassociatedwithnonfatalAIDSandseriousnonAIDSeventsamongadultsinfectedwithHIV.AIDS201024:697.
16. BhaskaranK,HamoudaO,SannesM,etal.ChangesintheriskofdeathafterHIVseroconversioncomparedwithmortalityinthegeneralpopulation.JAMA2008300:51.
17. GranichRM,GilksCF,DyeC,etal.UniversalvoluntaryHIVtestingwithimmediateantiretroviraltherapyasastrategyforeliminationofHIVtransmission:amathematicalmodel.Lancet2009373:48.
18. PhillipsAN,LeenC,WilsonA,etal.RiskofextensivevirologicalfailuretothethreeoriginalantiretroviraldrugclassesoverlongtermfollowupfromthestartoftherapyinpatientswithHIVinfection:anobservationalcohortstudy.Lancet2007370:1923.
19. KhannaN,OpravilM,FurrerH,etal.CD4+TcellcountrecoveryinHIVtype1infectedpatientsis
decreaseratesofperinatalHIVtransmissionaswellastotreatthemother.Theevidenceforthisrecommendation,thetimingofARTrelativetostageofpregnancy,andthechoiceofagentsisfoundelsewhere.(See"PrenatalevaluationandintrapartummanagementoftheHIVinfectedpatientinresourcerichsettings"and"UseofantiretroviralmedicationsinpregnantHIVinfectedpatientsandtheirinfantsinresourcerichsettings".)
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sour 11/13
independentofclassofantiretroviraltherapy.ClinInfectDis200847:1093.20. NashD,KatyalM,BrinkhofMW,etal.Longtermimmunologicresponsetoantiretroviraltherapyinlow
incomecountries:acollaborativeanalysisofprospectivestudies.AIDS200822:2291.21. GarcaF,deLazzariE,PlanaM,etal.LongtermCD4+Tcellresponsetohighlyactiveantiretroviral
therapyaccordingtobaselineCD4+Tcellcount.JAcquirImmuneDeficSyndr200436:702.22. MocroftA,PhillipsAN,GatellJ,etal.NormalisationofCD4countsinpatientswithHIV1infectionand
maximumvirologicalsuppressionwhoaretakingcombinationantiretroviraltherapy:anobservationalcohortstudy.Lancet2007370:407.
23. KelleyCF,KitchenCM,HuntPW,etal.IncompleteperipheralCD4+cellcountrestorationinHIVinfectedpatientsreceivinglongtermantiretroviraltreatment.ClinInfectDis200948:787.
24. StrategiesforManagementofAntiretroviralTherapy(SMART)StudyGroup,EmeryS,NeuhausJA,etal.Majorclinicaloutcomesinantiretroviraltherapy(ART)naiveparticipantsandinthosenotreceivingARTatbaselineintheSMARTstudy.JInfectDis2008197:1133.
25. MooreRD,GeboKA,LucasGM,KerulyJC.RateofcomorbiditiesnotrelatedtoHIVinfectionorAIDSamongHIVinfectedpatients,byCD4cellcountandHAARTusestatus.ClinInfectDis200847:1102.
26. GiorgiJV,HultinLE,McKeatingJA,etal.Shortersurvivalinadvancedhumanimmunodeficiencyvirustype1infectionismorecloselyassociatedwithTlymphocyteactivationthanwithplasmavirusburdenorviruschemokinecoreceptorusage.JInfectDis1999179:859.
27. GandhiRT,SpritzlerJ,ChanE,etal.EffectofbaselineandtreatmentrelatedfactorsonimmunologicrecoveryafterinitiationofantiretroviraltherapyinHIV1positivesubjects:resultsfromACTG384.JAcquirImmuneDeficSyndr200642:426.
28. RobbinsGK,SpritzlerJG,ChanES,etal.IncompletereconstitutionofTcellsubsetsoncombinationantiretroviraltherapyintheAIDSClinicalTrialsGroupprotocol384.ClinInfectDis200948:350.
29. StrategiesforManagementofAntiretroviralTherapy(SMART)StudyGroup,ElSadrWM,LundgrenJ,etal.CD4+countguidedinterruptionofantiretroviraltreatment.NEnglJMed2006355:2283.
30. SilverbergMJ,NeuhausJ,BowerM,etal.RiskofcancersduringinterruptedantiretroviraltherapyintheSMARTstudy.AIDS200721:1957.
31. SzczechLA,GuptaSK,HabashR,etal.TheclinicalepidemiologyandcourseofthespectrumofrenaldiseasesassociatedwithHIVinfection.KidneyInt200466:1145.
32. MarrasD,BruggemanLA,GaoF,etal.ReplicationandcompartmentalizationofHIV1inkidneyepitheliumofpatientswithHIVassociatednephropathy.NatMed20028:522.
33. LucasGM,EustaceJA,SozioS,etal.HighlyactiveantiretroviraltherapyandtheincidenceofHIV1associatednephropathy:a12yearcohortstudy.AIDS200418:541.
34. EstrellaM,FineDM,GallantJE,etal.HIVtype1RNAlevelasaclinicalindicatorofrenalpathologyinHIVinfectedpatients.ClinInfectDis200643:377.
35. KalayjianRC,FranceschiniN,GuptaSK,etal.SuppressionofHIV1replicationbyantiretroviraltherapyimprovesrenalfunctioninpersonswithlowCD4cellcountsandchronickidneydisease.AIDS200822:481.
36. AttaMG,FineDM,KirkGD,etal.SurvivalduringrenalreplacementtherapyamongAfricanAmericansinfectedwithHIVtype1inurbanBaltimore,Maryland.ClinInfectDis200745:1625.
37. GuptaSK,EustaceJA,WinstonJA,etal.GuidelinesforthemanagementofchronickidneydiseaseinHIVinfectedpatients:recommendationsoftheHIVMedicineAssociationoftheInfectiousDiseasesSocietyofAmerica.ClinInfectDis200540:1559.
38. GuidelinesfortheclinicalmanagementandtreatmentofHIVinfectedadultsinEurope.EuropeanAIDSClinicalSociety.
39. HeatonRK,CliffordDB,FranklinDRJr,etal.HIVassociatedneurocognitivedisorderspersistintheeraofpotentantiretroviraltherapy:CHARTERStudy.Neurology201075:2087.
40. GrulichAE,vanLeeuwenMT,FalsterMO,VajdicCM.IncidenceofcancersinpeoplewithHIV/AIDScomparedwithimmunosuppressedtransplantrecipients:ametaanalysis.Lancet2007370:59.
41. MonforteAd,AbramsD,PradierC,etal.HIVinducedimmunodeficiencyandmortalityfromAIDSdefiningandnonAIDSdefiningmalignancies.AIDS200822:2143.
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sour 12/13
42. MarinB,ThibautR,BucherHC,etal.NonAIDSdefiningdeathsandimmunodeficiencyintheeraofcombinationantiretroviraltherapy.AIDS200923:1743.
43. ProsperiMC,CozziLepriA,CastagnaA,etal.IncidenceofmalignanciesinHIVinfectedpatientsandprognosticroleofcurrentCD4cellcount:evidencefromalargeItaliancohortstudy.ClinInfectDis201050:1316.
44. SilverbergMJ,ChaoC,LeydenWA,etal.HIVinfectionandtheriskofcancerswithandwithoutaknowninfectiouscause.AIDS200923:2337.
45. BiggarRJ,ChaturvediAK,GoedertJJ,etal.AIDSrelatedcancerandseverityofimmunosuppressioninpersonswithAIDS.JNatlCancerInst200799:962.
46. CliffordGM,PoleselJ,RickenbachM,etal.CancerriskintheSwissHIVCohortStudy:associationswithimmunodeficiency,smoking,andhighlyactiveantiretroviraltherapy.JNatlCancerInst200597:425.
47. LichtensteinKA,ArmonC,BuchaczK,etal.LowCD4+TcellcountisariskfactorforcardiovasculardiseaseeventsintheHIVoutpatientstudy.ClinInfectDis201051:435.
48. EwingsFM,BhaskaranK,McLeanK,etal.SurvivalfollowingHIVinfectionofacohortfollowedupfromseroconversionintheUK.AIDS200822:89.
49. QuinnTC,WawerMJ,SewankamboN,etal.Viralloadandheterosexualtransmissionofhumanimmunodeficiencyvirustype1.RakaiProjectStudyGroup.NEnglJMed2000342:921.
50. HammerSM,SquiresKE,HughesMD,etal.AcontrolledtrialoftwonucleosideanaloguesplusindinavirinpersonswithhumanimmunodeficiencyvirusinfectionandCD4cellcountsof200percubicmillimeterorless.AIDSClinicalTrialsGroup320StudyTeam.NEnglJMed1997337:725.
51. DegenhardtL,MathersB,VickermanP,etal.PreventionofHIVinfectionforpeoplewhoinjectdrugs:whyindividual,structural,andcombinationapproachesareneeded.Lancet2010376:285.
52. ZolopaA,AndersenJ,PowderlyW,etal.EarlyantiretroviraltherapyreducesAIDSprogression/deathinindividualswithacuteopportunisticinfections:amulticenterrandomizedstrategytrial.PLoSOne20094:e5575.
53. BicanicT,MeintjesG,RebeK,etal.ImmunereconstitutioninflammatorysyndromeinHIVassociatedcryptococcalmeningitis:aprospectivestudy.JAcquirImmuneDeficSyndr200951:130.
54. PalellaFJJr,DelaneyKM,MoormanAC,etal.Decliningmorbidityandmortalityamongpatientswithadvancedhumanimmunodeficiencyvirusinfection.HIVOutpatientStudyInvestigators.NEnglJMed1998338:853.
55. MarschnerIC,CollierAC,CoombsRW,etal.Useofchangesinplasmalevelsofhumanimmunodeficiencyvirustype1RNAtoassesstheclinicalbenefitofantiretroviraltherapy.JInfectDis1998177:40.
56. SterneJA,HernnMA,LedergerberB,etal.LongtermeffectivenessofpotentantiretroviraltherapyinpreventingAIDSanddeath:aprospectivecohortstudy.Lancet2005366:378.
57. HIVCAUSALCollaboration,RayM,LoganR,etal.TheeffectofcombinedantiretroviraltherapyontheoverallmortalityofHIVinfectedindividuals.AIDS201024:123.
58. HoggRS,YipB,ChanKJ,etal.RatesofdiseaseprogressionbybaselineCD4cellcountandviralloadafterinitiatingtripledrugtherapy.JAMA2001286:2568.
59. CameronDW,HeathChiozziM,DannerS,etal.RandomisedplacebocontrolledtrialofritonavirinadvancedHIV1disease.TheAdvancedHIVDiseaseRitonavirStudyGroup.Lancet1998351:543.
60. FischlMA,RichmanDD,GriecoMH,etal.Theefficacyofazidothymidine(AZT)inthetreatmentofpatientswithAIDSandAIDSrelatedcomplex.Adoubleblind,placebocontrolledtrial.NEnglJMed1987317:185.
61. WhenToStartConsortium,SterneJA,MayM,etal.TimingofinitiationofantiretroviraltherapyinAIDSfreeHIV1infectedpatients:acollaborativeanalysisof18HIVcohortstudies.Lancet2009373:1352.
62. RodrguezB,SethiAK,CheruvuVK,etal.PredictivevalueofplasmaHIVRNAlevelonrateofCD4TcelldeclineinuntreatedHIVinfection.JAMA2006296:1498.
63. MayM,SterneJA,SabinC,etal.PrognosisofHIV1infectedpatientsupto5yearsafterinitiationofHAART:collaborativeanalysisofprospectivestudies.AIDS200721:1185.
64. JanA,EsteveA,MirJM,etal.DeterminantsofHIVprogressionandassessmentoftheoptimaltimetoinitiatehighlyactiveantiretroviraltherapy:PISCISCohort(Spain).JAcquirImmuneDeficSyndr200847:212.
-
22/1/2015 WhentoinitiateantiretroviraltherapyinHIVinfectedpatients
http://catalogo.fucsalud.edu.co:2056/contents/whentoinitiateantiretroviraltherapyinhivinfectedpatients?topicKey=ID%2F3777&elapsedTimeMs=0&sour 13/13
Disclosures:JohnGBartlett,MDNothingtodisclose.MartinSHirsch,MDNothingtodisclose.JenniferMitty,MD,MPHEmployeeofUpToDate,Inc.Contributordisclosuresarereviewedforconflictsofinterestbytheeditorialgroup.Whenfound,theseareaddressedbyvettingthroughamultilevelreviewprocess,andthroughrequirementsforreferencestobeprovidedtosupportthecontent.AppropriatelyreferencedcontentisrequiredofallauthorsandmustconformtoUpToDatestandardsofevidence.Conflictofinterestpolicy
65. HIVCAUSALCollaboration,CainLE,LoganR,etal.WhentoinitiatecombinedantiretroviraltherapytoreducemortalityandAIDSdefiningillnessinHIVinfectedpersonsindevelopedcountries:anobservationalstudy.AnnInternMed2011154:509.
66. SabineC,AntiretroviralTherapy(ART)CohortCollaboration.AIDSeventsamongindividualsinitiatingHAART:dosomepatientsexperienceagreaterbenefitfromHAARTthanothers?AIDS200519:1995.
67. KitahataMM,GangeSJ,AbrahamAG,etal.EffectofearlyversusdeferredantiretroviraltherapyforHIVonsurvival.NEnglJMed2009360:1815.
68. SaxPE,BadenLR.Whentostartantiretroviraltherapyreadywhenyouare?NEnglJMed2009360:1897.69. LundgrenJD,PhillipsAN,NeatonJ.Uncertaintyastowhethertheuseofantiretroviraltherapyforpersons
recentlyinfectedwithHIVhasafavorablerisktobenefitratio.ClinInfectDis200948:1162authorreply1162.
70. AntiretroviralTherapyCohortCollaboration.CausesofdeathinHIV1infectedpatientstreatedwithantiretroviraltherapy,19962006:collaborativeanalysisof13HIVcohortstudies.ClinInfectDis201050:1387.
71. OkuliczJF,GranditsGA,WeintrobAC,etal.CD4TcellcountreconstitutioninHIVcontrollersafterhighlyactiveantiretroviraltherapy.ClinInfectDis201050:1187.
Topic3777Version32.0
Disclosures